Amniotics
Amniotics announces the outcome of the exercise of warrants series TO 3
The board of directors of Amniotics AB (publ) (“Amniotics” or the “Company”) today announces the outcome of the exercise period for warrants series TO 3 (the “Warrants”), which were issued in connection with the Company’s rights issue of units which was announced on August 31, 2023 (the “Rights Issue”). The subscription rate was approximately 0.89 per cent and Amniotics thereby receives approximately SEK 225,043.84 before issue costs. In accordance with what was previously communicated in the year-end report for 2023, the Company's management and board of directors are actively working to identify and evaluate various possible solutions to secure the Company's financing needs.
In total, Amniotics issued 2,502,044,100 units in the Rights Issue, each consisting of one (1) share and one (1) Warrant. One (1) Warrant entitled the right to subscribe for one (1) new share in the Company at an exercise price of SEK 0.01 per share. The exercise period of the Warrants ran from and including February 26, 2024, to and including March 8, 2024. The final outcome shows a subscription rate of approximately 0.89 per cent, meaning that 22,504,384 Warrants were utilized for subscription of 22,504,384 shares. Exercised Warrants has been replaced with interim shares pending registration with the Swedish Companies Registration Office. The interim shares are expected to be converted into shares during week 12, 2024.
Through the exercise of the Warrants the Company receives approximately SEK 225,043.84 before issue costs. The total number of shares in Amniotics increases by 22,504,384, from 2,710,547,775 to 2,733,052,159. The share capital in Amniotics increases by SEK 54,010.52160, from SEK 6,505,314.66 to SEK 6,559,325.18160.
Advisors
Redeye AB acts as financial advisor and issuer agent and Setterwalls Advokatbyrå AB acts as legal advisor to Amniotics in connection with the Rights Issue. Nordic issuing AB acts as issuing agency in connection with the Rights Issue.
IMPORTANT INFORMATION
The information in this press release does not contain or constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants or other securities in Amniotics. Invitation to the persons concerned to subscribe for units consisting of shares and Warrants in Amniotics has only taken place through the prospectus that Amniotics published on October 10, 2023.
For more information please contact
Marcus Larsson
CEO, Amniotics AB
Phone: +46 (0) 763 0840 91
Email: ml@amniotics.com
1/2
About Amniotics
Amniotics AB (publ) is a clinical stage biotech company, developing innovative therapies, based on amniotic fluid derived stem cells. The company develops therapies to treat diseases where effective treatments are currently lacking.
Amniotics has an established GMP-facility, approved and licensed by the Swedish Medical Products Agency. The company has capabilities as a Contract Development and Manufacturing Organization (CDMO) for other biotech companies.
Amniotics is headquartered in Lund, Sweden.
The company is listed at Nasdaq First North Growth Market in Stockholm. Amniotics Certified Adviser at First North is Redeye AB.
Learn more at www.amniotics.com.
Attachments
2/2
| Datum | 2024-03-11, kl 16:00 |
| Källa | MFN |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!